Related Experiment Video
Updated: May 8, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
New drug targets in metastatic melanoma
1Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA, USA.
Abstract:
Over the past 30 years, and despite extensive clinical research, the treatment options for metastatic melanoma have been limited. Single-agent and combination chemotherapy, hormonal therapy, biochemotherapy, immunotherapy, targeted agent therapy and combination regimes have failed to show significant improvement in overall survival. Recent advances and in-depth understanding of the biology of melanoma have contributed in the development of new agents and to a change in the consideration of melanoma as one of the most therapy-resistant malignancies. Since the discovery of activating mutations in the BRAF oncogene, there has been remarkable progress in the development of targeted therapies for unresectable and metastatic melanoma, with unprecedentedly high response rates. Inactivation of immune regulatory checkpoints that limit T cell responses to melanoma has provided clinically validated targets for cancer immunotherapy, resulting in durable tumour responses. The combination of both approaches may result in additional benefits. Here we discuss current molecular targeted treatment options, immunotherapy and promising ongoing research to develop new strategies to treat melanoma.
Insights
Metastatic melanoma treatment has advanced with BRAF inhibitors and immunotherapy, offering new hope. Combining these strategies may further improve outcomes for this challenging cancer.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Metastatic melanoma treatment has seen limited success with traditional therapies over the past 30 years.
- Melanoma is recognized as a highly therapy-resistant malignancy, necessitating novel treatment strategies.
Purpose of the Study:
- To review current molecular targeted treatment options for metastatic melanoma.
- To discuss the role of cancer immunotherapy in melanoma treatment.
- To explore promising research for novel melanoma treatment strategies.
Main Methods:
- Review of recent advances in understanding melanoma biology.
- Analysis of targeted therapies, focusing on BRAF oncogene mutations.
- Evaluation of immunotherapies targeting immune regulatory checkpoints.
Main Results:
- Activating BRAF mutations have led to targeted therapies with high response rates in unresectable and metastatic melanoma.
- Inactivation of immune checkpoints has yielded durable tumor responses through cancer immunotherapy.
- Combination approaches of targeted therapy and immunotherapy show potential for added benefits.
Conclusions:
- Targeted therapies and immunotherapies represent significant progress in metastatic melanoma treatment.
- Further research into novel strategies, including combination therapies, is crucial for improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle